Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Disarming the silent threat of ovarian cancer

Project description

Early detection of ovarian cancer

Ovarian cancer (OC) is the deadliest of female cancers, often called a ‘silent killer’. The EU-funded DISARM project will fill significant gaps in hereditary OC management by focusing on risk assessment and early detection. It will compare multifactorial risk assessment methods with standard practices in the Czech Republic Greece, Lithuania, and Portugal, while developing accurate and affordable early detection technologies in these countries, as well as the UK. Advanced digital tools will enhance clinical studies, and various activities will promote the adoption of DISARM solutions. The project will investigate conditions for applying proven solutions in OC risk assessment and gather evidence for new approaches in early detection. This initiative is part of the Cancer Mission cluster.

Objective

Ovarian cancer (OC) is the most lethal of female cancers, often termed a “silent killer”. DISARM’s overall approach to tackle the significant gaps in hereditary OC management lies in tackling both key elements of risk assessment and early detection. The project will investigate multifactorial risk assessment versus standard practices in 4 EU Member States (MS) (Lithuania, Portugal, Czech Republic, and Greece), and will upscale and validate a set of easy-to-use, highly accurate and affordable technologies in five countries (UK, Lithuania, Portugal, Czech Republic, and Greece). Several intelligent digital assets will optimally support and enhance our clinical studies, while a range of multifaceted activities will ensure the future uptake and adoption of DISARM solutions. The project aligns with the Innovation Action character of this topic by focusing on both mature technologies that can be upscaled in routine healthcare and on emerging technologies that have already shown a potential to justify larger scale validation activities. Our ultimate ambition is to holistically investigate the preconditions and set the stage for rolling out proven solutions in routine OC risk assessment, and in parallel to create further evidence for the introduction of novel promising elements in early detection programmes. DISARM gathers 26 partners from 12 countries (10 EU MS, the UK and Canada), thereby exhibiting a significant geographic coverage, strengthening European and international collaboration and ensuring widespread diffusion of the project results. This action is part of the Cancer Mission cluster of projects on ‘Prevention and Early Detection (early detection heritable cancers)

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-IA - HORIZON Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MISS-2024-CANCER-01

See all projects funded under this call

Coordinator

EREVNITIKO PANEPISTIMIAKO INSTITOUTO SYSTIMATON EPIKOINONION KAI YPOLOGISTON
Net EU contribution
€ 937 250,00
Address
PATISION 42
106 82 ATHINA
Greece
Region
Αττική Aττική Κεντρικός Τομέας Αθηνών
Activity type
Research Organisations
Links
Total cost
€ 937 250,00

Participants (27)